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TIME INTERVAL TO DIAGNOSIS OF BLADDER CANCER AND ITS ASSOCIATED
OUTCOMES. Lara K. Suh and Edward M. Uchio. Section of Urology, Department of
Surgery, Yale University, School of Medicine, New Haven, CT.

The purpose of this study is to investigate whether a prolonged delay in
diagnosis of bladder cancer will result in worse outcomes for those patients, compared
to those patients with a shorter diagnostic time interval. Data was collected on 247
patients newly diagnosed with transitional cell carcinoma of the bladder from January
1996 to December 2006 (10 years). The medical records of these patients were
reviewed for demographics, pathological stage, date of consultation to the genitourinary
(GU) service, and date of diagnosis by transurethral resection of bladder tumor (TURBT).
The specialty delay was calculated as the time between the date of consultation to the
GU service to the establishment of a diagnosis by TURBT. Univariate analyses were
performed to test the association of specialty delay with clinical features and all-cause
mortality. The median specialty delay in this study was 100 days. There was a trend
towards a longer specialty delay for muscle-invasive disease (T2-T4) in comparison to
superficial disease (Ta and T1). There was a significant correlation between all-cause
mortality and increasing clinical stage (p=0.01). There was a paradoxical finding that
patients with a specialty delay greater than 100 days had a significant reduction in allcause death in comparison to patients with a specialty delay of 100 days or less (relative
risk=0.59; 95% CI 0.36-0.90; p=0.01). In conclusion, this study did not confirm the
hypothesis that a prolonged specialty delay in patients diagnosed with bladder cancer
would result in a worse prognosis. In fact, there was a paradoxical finding that patients
with a specialty delay greater than the median delay of 100 days had a better prognosis.
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INTRODUCTION
Bladder cancer is the second most common malignancy of the
genitourinary tract. In the United States, it is the fourth most common cancer in
men, accounting for 6.2% of all cancer cases and it is the eighth most common
cancer in women, accounting for 2.5% of all cancer cases (1). An estimated
61,420 individuals in the United States will be newly diagnosed with bladder
cancer in 2006 (1). Of those individuals, 44,690 are male and 16,730 are female,
making the incidence of bladder cancer more than 2.5 times more common in
men (1). The estimated number of bladder cancer deaths expected to occur in
the United States in 2006 is 13,060, of which 8,990 are male, making bladder
cancer the ninth most common cause of cancer death in American men (1).
Bladder cancer accounts for 3.1% of all cancer deaths in men and 1.5% in
women. Up until the mid 1970s, the mortality rates for bladder cancer in the
United States rose to a value of 5.1/100,000 in men and 1.5/100,000 in women,
and then started to decline (2). The pattern of decline in mortality, which was
observed mainly in men, reflects the pattern of decreased exposure to cigarette
smoking and occupational carcinogens seen over the past two decades. These
patterns are consistent with those of lung cancer mortality in men, which showed
downward trends in countries that implemented antismoking campaigns.
Bladder cancer is primarily a disease of the elderly with the median age at
diagnosis increasing from 69 years of age in the time period of 1974-1978 to 73
years of age in the time period of 1999-2003 (3). The incidence of bladder
cancer also increases with age from roughly 142 per 100,000 men and 33 per
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100,000 women age 65-69 years to 296 per 100,000 men and 74 per 100,000
women 85 years old or older (4).
Many different environmental exposures, which include occupational
exposure to chemicals, cigarettes, caffeine, analgesics, drinking water quality,
artificial sweeteners, and chemotherapeutic agents, have been studied in an
attempt to determine a relationship with the development and progression of
bladder cancer. However, only industrial chemicals and cigarette smoking have
the epidemiologic, molecular, and histopathologic evidence to confirm this
relationship. It has been estimated that between 4 and 7% of bladder cancer
cases are attributable to occupational factors in Europe and up to 20% in the
United States (2, 4). Most bladder carcinogens from occupational exposures are
aromatic amines and their derivatives. Studies of German dye workers
performed more than a century ago suggested that aniline containing dyes and
arylamines, such as 2-naphthylamine, were responsible for the high incidence of
bladder tumors seen in these workers (2). The association between bladder
cancer and cigarette smoking is also well established. The relative risk (RR) that
a smoker will develop bladder cancer is 2-4 times that of non-smokers (2). This
risk increases with the number of cigarettes smoked, the duration of smoking,
and the degree of inhalation of smoke (4). There is also an association with
smoking cessation and a decline in the relative risk of bladder cancer that is
proportional to the duration of abstinence (2). Although epidemiologic and
experimental evidence favors a strong role for chemical carcinogens in the
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etiology of bladder cancer, many cases arise with no obvious exposure to known
carcinogens.
The spectrum of bladder cancer includes superficial, muscle-invasive, and
metastatic disease, each with its own clinical behavior, prognosis, and treatment.
Approximately 90% of all bladder cancers are transitional cell carcinomas, and all
further discussion of bladder cancer in this study will refer to transitional cell
carcinoma. The most commonly used staging system is the American Joint
Committee on Cancer TNM system, which allows for a precise and simultaneous
description of the primary tumor stage, the status of lymph nodes, and metastatic
sites. Papillary bladder tumors that are limited to the bladder epithelium are
classified as stage Ta lesions, while any tumor invading the lamina propria or
submucosa is classified as a stage T1 tumor. Any lesion that invades into the
muscle, but is still confined within the bladder is classified as a stage T2 tumor.
The T3 category includes tumors that invade the perivesical fat and T4 disease
includes tumors that extend into adjacent organs. Carcinoma in-situ (CIS) is a
flat lesion of the urothelium characterized by the presence of cells containing
large, irregular hyperchromatic nuclei with prominent nucleoli. CIS disease has a
variable natural history, but many cases progress to invasive disease. At the
time of diagnosis, approximately 70% of bladder tumors are classified as
superficial disease (stage Ta, T1, and CIS) and the remaining 30% are muscleinvasive bladder tumors (stage T2 to T4) (5). Among the superficial bladder
tumors, 70% present as Ta lesions, 20% as T1 lesions, and 10% as carcinoma
in-situ (5). The clinical stage of a bladder tumor provides a reasonable estimate
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of its biologic potential and it is strongly correlated to tumor recurrence,
progression, and survival. For those patients with disease limited to the
submucosal layer and above, which includes stage Ta, T1, and CIS, the diseasefree survival is 80-88%. For patients with muscle-invasive bladder cancer, the
disease-free survival steadily declines: 53-80% for T2, 39-68% for T3, and 2540% for T4 tumors (6).
Bladder tumors are also classified by histologic grade as either low or high
grade, based upon the degree of resemblance to the normal tissue architecture.
About 60% of newly diagnosed bladder tumors are low-grade, superficial (stage
Ta or T1) lesions. The remaining 40% of newly diagnosed bladder tumors are
high-grade lesions, with more than half of those being muscle-invasive (stage T2
or above) at the time of diagnosis (7). The most important prognostic parameters
for tumor recurrence and subsequent cancer progression are tumor grade, tumor
stage, and presence of carcinoma in-situ.
Superficial bladder cancer includes those stages that are not muscleinvasive, stages Ta, T1, and CIS, and represents a spectrum of tumors with a
wide range of clinical behaviors. Multiple recurrent low-grade Ta tumors have a
high risk of recurrence but a low risk of progression into muscle-invasive disease.
On the other hand, multiple recurrent high-grade T1 tumors have a high risk for
both recurrence and progression. For those patients diagnosed with superficial
bladder cancer, the most important prognostic factors for recurrence are the
number of tumors, their size, and the prior recurrence rate (8). A multivariate
analysis of prognostic factors performed by Millan-Rodriguez et al. (9)
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demonstrated that the only mortality prognostic factors are high-grade disease
and carcinoma in-situ. They found that high grade disease has a 14 times higher
mortality risk than that of low grade disease (95% CI 1.8-109) and associated
carcinoma in-situ had a 3 times higher mortality risk than without CIS disease
(95% CI 1.4-6.6). A study of 333 patients with superficial bladder cancer by
Allard et al. (10) demonstrated that the probability of recurrence at one year after
transurethral resection (TURBT) increased with the presence of certain tumor
characteristics: multiplicity, tumor size > 3cm, stage T1, and high grade. A
patient with superficial bladder cancer and none of the aforementioned tumor
characteristics has about a 15% probability of recurrence at one year, while a
patient with 3 or 4 of the tumor characteristics will have a 70% probability of
recurrence at one year. Kurth et al. (11) studied 576 patients with superficial
bladder tumors and found that tumors recurred in 54% of the study group and 76
patients progressed to T2 or worse. The study also observed a tumor
progression rate ranging from about 7% to 41%, depending on three main factors:
tumor size, grade, and prior recurrence rate.
The clinical stage and grade of a bladder tumor is also an important
variable in tailoring treatment decisions for patients diagnosed with bladder
cancer. Patients with low grade, small Ta tumors who are at low risk of
progression may be treated with transurethral resection alone, followed by
surveillance. Patients with high grade, large T1 tumors who are at a higher risk
of progression and recurrence are candidates for intravesical chemotherapy
following complete transurethral resection or early cystectomy, especially if the
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presentation is multifocal. For patients with muscle-invasive bladder cancer, the
treatment of choice is radical cystectomy. Improvements in surgical technique
and perioperative care have reduced perioperative mortality to 3% and overall
survival after radical cystectomy is 60% at 5 years (12). Recent studies have
suggested that a delay in radical cystectomy for the treatment of muscle-invasive
bladder cancer can adversely affect patient survival and result in worse
pathological stage. Sanchez-Ortiz et al. (13) studied 290 patients who
underwent radical cystectomy for muscle-invasive bladder cancer and found that
a delay in surgery of greater than 12 weeks was associated with advanced
pathological stage and decreased survival. Chang et al. (14) studied 303
patients with muscle-invasive bladder cancer who underwent radical cystectomy
to determine whether a delay in treatment influenced pathological staging
outcome. This study found that 81% of the patients with a treatment delay of
greater than 90 days had stage T3 or higher disease, compared to 52% of those
patients with a treatment delay less than 90 days (81% versus 52%, chi-square
analysis p=0.01). Lee et al. (15) studied the timing from stage T2 bladder cancer
diagnosis to radical cystectomy and its impact on survival. This study observed a
significant disease specific survival and overall survival advantage in patients
treated 93 days or less compared to greater than 93 days (p=0.05 and 0.02,
respectively).
Similar studies have been performed to evaluate the impact of treatment
delays for prostate cancer. The SEARCH database study group (16) studied
almost 900 men with low risk prostate cancer who underwent radical
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prostatectomy and observed an increased risk of biochemical progression in men
with delays of greater than 180 days compared to a delay of less than 90 days
(RR 2.75, 95% CI 1.40 to 5.43). Similarly, Nguyen et al. (17) found that delays in
initiating radiation therapy adversely influence PSA outcome in patients with
high-risk disease. In their cohort of high-risk patients, the PSA failure-free
survival estimates at 5 years for patients with a delay less than 2.5 months was
55%, compared to 39% for patients with a delay of 2.5 months or more (p=0.014).
These studies investigated only the treatment delay, defined as the time
interval from diagnosis to treatment. However, delayed treatment for a disease is
comprised of two components, the diagnostic delay and the treatment delay.
The diagnostic delay can be further divided into the patient delay and the hospital
delay (see Figure 1). The patient delay is defined as the time interval from the
patient’s first awareness of symptoms to the first medical consultation. The
hospital delay is defined as the time interval from the medical consultation to the
diagnosis. At healthcare providers, such as the Veterans Affairs (VA)
Connecticut Healthcare System, the hospital delay can be further divided into two
phases, the primary care delay and the specialisty delay. The primary care delay
is defined as the time interval from consultation with a primary care physician
(PCP) to the first specialty consultation. The specialty delay is defined as the
time interval from the first specialty consultation to diagnosis.
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Figure 1. The different components of delay from first symptom to treatment.
Although, there have been recent studies investigating the consequences
of a prolonged treatment delay in bladder cancer, there have been few studies
evaluating the effect of a prolonged diagnosis delay in the outcomes of bladder
cancer patients. The assessment of diagnostic delay is difficult to study because
of the variations in referral methods, which can differ according to the patient’s
insurance coverage and whether their physician is in a private practice setting or
in an academic setting. A study to assess diagnostic delay is best performed
within a healthcare system that includes primary care physicians and a
standardized referral method, such as a Health Maintenance Organization (HMO)
or a Veterans Administration (VA) system. One such study of diagnostic delay
by Liedberg et al. (18) found that patients with T1 bladder tumors and a
diagnostic delay of greater than 6 months showed a relative risk of bladder
cancer death of 2.0 (95% CI 0.84-4.7;p=0.12), compared to those with a shorter
delay. However, patients with muscle invasive tumors (stage T2-T4) with a
greater than 6 month diagnostic delay had a relative risk of bladder cancer death
of 0.39 (95% CI 0.23-0.69; p=0.001). There has been mixed evidence regarding
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the affects of a delayed diagnosis on survival and prognosis for other
malignancies, such as breast cancer, colorectal cancer, and lung cancer (19-21).
Mansson et al. (22) investigated the various factors that may play a role in
the different components of delay in the diagnosis of bladder cancer. They found
that the median patient delay was 15 days (mean 141, range 0-2857) and there
was no relationship between this delay and age or gender. However, they did
find that the type of symptoms was an important factor in patient delay with
hematuria prompting patients to seek medical advice more quickly than urgency
of micturition or pain (median 5 days vs. 45 and 38 days, respectively, p<0.001).
The median hospital delay was 62 days overall with a positive correlation
between hospital delay and the number of referrals. As with patient delay, the
type of presenting symptoms influenced hospital delay: hematuria with pain had
a shorter delay than hematuria alone, and urgency had the longest delay
(medians 44, 53 and 114 days, respectively, p<0.001). When comparing tumor
stage in relation to delays, the median patient delay was longer with advanced
cancer than in those with superficial tumors, but this difference was not
statistically significant. No correlation was found between tumor stage and
hospital delay.
The results of these studies demonstrate that the impact of a prolonged
diagnostic and/or treatment delay on prognosis is complex and a better
understanding of this relationship is needed.
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HYPOTHESIS
This study will test the hypothesis that a prolonged delay in diagnosis of
transitional cell carcinoma of the bladder will result in worse outcomes for those
patients compared to those patients with a shorter diagnostic time interval.

SPECIFIC AIMS
The primary aim of this study is to investigate the diagnostic delay for patients
newly diagnosed with bladder cancer at the VA Connecticut Healthcare Systems
and its association, if any, to bladder cancer recurrence and all-cause mortality.
This primary aim will be achieved by the following:
1. Calculation of the specialty delay, defined as the time interval from
genitourinary (GU) service consultation to diagnosis of bladder cancer, for
all study subjects.
2. Determine if there is an association between a prolonged specialty delay
(greater than 100 days) and incidence of bladder cancer recurrence.
3. Determine if there is a relationship between a prolonged specialty delay
(greater than 100 days) and incidence of all-cause death.
A secondary aim of this study is to determine the clinical outcomes of patients
newly diagnosed with bladder cancer at the VA Connecticut Healthcare Systems.
This secondary aim will be achieved by the following:
1. Determine the distribution of clinical stages in patients newly diagnosed
with bladder cancer at the VA Connecticut Healthcare Systems.
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2. Determine the mean specialty delay for the entire study cohort and for
each clinical stage.
3. Determine if there is a relationship between specialty delays and clinical
stage.
4. Determine the incidence of bladder cancer recurrence and all-cause death
for the entire study cohort and for each clinical stage.
5. Determine if there is a relationship between clinical stage and incidence of
all-cause death.

METHODS
Data on patients diagnosed with bladder cancer from 1996 to 2006 (10
years) were reviewed after obtaining Institutional Review Board approval from
the Veterans Affairs Connecticut Healthcare Systems. The analyzed data
derived from 317 subjects with the diagnosis of malignant neoplasm of the
bladder made at the VA Connecticut Healthcare Systems. A report was
generated by the Department of Surgery at the VA Connecticut Healthcare
Systems using the International Classification of Disease (ICD-9 billing codes
188.0 through 188.9), which identified all patients diagnosed with a malignant
neoplasm of the bladder from January 1996 to December 2006. Of the 317
cases, 42 subjects were excluded because there were no referrals to the
genitourinary (GU) service noted in their medical records, so a specialty delay
interval could not be calculated. An additional 28 patients were excluded from
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the study for recurrent bladder cancer (n=19), squamous cell carcinoma (n=4),
adenocarcinoma (n=3), sarcomatoid carcinoma (n=1), and small cell carcinoma
(n=1). The remaining 247 patients with a diagnosis of transitional cell carcinoma
of the bladder established in January 1996 through December 2006 comprised
the study cohort.
The data collected included the date of consultation to the GU service, the
date of diagnosis, and the dates of any recurrences diagnosed by transurethral
resection of bladder tumor (TURBT). Patients were referred to the GU service by
their primary care physician using the electronic consult request in the patient’s
electronic medical record. In most instances, the date of referral to the GU
service corresponds to the date the patient first presents to their primary care
physician with their urinary symptoms (i.e. gross hematuria, dysuria, urgency of
micturition, etc.). The date of diagnosis is defined as the date of the patient’s
TURBT that initially revealed a malignancy of the bladder on pathology report.
Pathology reports for all follow-up TURBT’s were reviewed for evidence of
recurrent malignant bladder tumors. Information on the patient’s status at the
time of censor (February 1, 2007) was also collected. The date of the patient’s
last follow-up visit, if alive, or the date of death was noted. Clinical details
collected included the number and size of tumors. Pathological details and
American Joint Committee on Cancer (AJCC) TNM classification were also
collected. Information on demographics, such as age and gender, were also
collected.
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Following the collection of the data, all identifying information (name,
patient ID number, SSN) was removed from the data set and was filed separately,
with access limited to responsible investigators. All records reviewed remained
confidential and any analytical use of the records did not refer to identifying
information.
For those patients who were alive at the censor date, the follow-up interval
was calculated as the time from diagnosis to the latest date of bladder cancer
recurrence, or the censor date for patients who did not experience a recurrence.
For those patients who did not survive during the study period, the follow-up
interval was calculated as the time from diagnosis to the date of death. The
mean follow-up interval was calculated for the entire cohort.
The specialty delay interval was calculated as the time from consultation
to the GU service to the diagnosis by TURBT. The mean specialty delay was
calculated for the entire cohort and for each clinical stage. The mean specialty
delay was also calculated for those patients diagnosed with superficial disease,
defined as clinical stage Ta and T1, and muscle-invasive disease, defined as
clinical stage T2 through T4. A one-way analysis of variance (ANOVA) was used
to compare the mean specialty delays between each of the clinical stages using
the Statistical Analysis ToolPak (Microsoft Excel, Microsoft Corp., Redmond,
WA). An unpaired Student’s t-test was used to compare the mean specialty
delays of the superficial disease group and the muscle-invasive disease group.
The number of patients with a recurrence of malignant bladder tumor
diagnosed on a follow-up TURBT was used to calculate the incidence of
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recurrence. Following stratification by clinical stage, the incidence of recurrence
was only calculated for stage Ta and T1. The incidence of recurrence was not
calculated for the muscle-invasive tumors (clinical stage T2 through T4) since the
standard of treatment for these patients would be a radical cystectomy and
recurrence in the bladder would not occur.
The number of patients who died from any cause was used to calculate
the incidence of all-cause death for each clinical stage. A regression analysis
was performed to determine the relationship between all-cause death and
increasing clinical stage using the Statistical Analysis ToolPak in Microsoft Excel.
The entire cohort was divided into two specialty delay groups using the
median specialty delay of 100 days, which led to one specialty delay group of
100 days or less and another specialty delay group of greater than 100 days.
For patients diagnosed in each superficial clinical stage, the incidence of bladder
tumor recurrence was calculated for both of the specialty delay groups. Relative
risk ratios were calculated comparing those patients with a specialty delay of
greater than 100 days versus those patients with a specialty delay of 100 days or
less. Two-group comparisons were performed using the Fischer’s exact test
(GraphPad Software, San Diego, CA). For the entire cohort, the incidence of
death from all causes was calculated for both specialty delay groups. The
incidence of disease-specific death was not calculated in this study due to
unavailability of data regarding cause of death. Relative risk ratios were
calculated and two-group comparisons were performed using the Fischer’s exact
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test, as described above. All relative risk ratios were calculated with 95%
confidence intervals and all P-values were two-sided.

RESULTS
Overall, 247 patients met the criteria for inclusion in this study.
Demographic and pathologic features of the patients from the overall cohort are
shown in Table A. The cohort consisted of 244 men (98.8%) and 3 women
(1.2%) with a mean age of 70.5 years (standard deviation 9.8) and a mean
follow-up interval of 2.8 years (range 12 days to 11.1 years). The majority of the
cohort had superficial bladder cancer at the time of diagnosis, with 120 patients
presenting with clinical Ta disease and 81 patients with clinical T1 disease. Six
patients had only carcinoma in-situ (CIS) disease at diagnosis, while the
remaining 40 patients had muscle-invasive bladder cancer (34 patients with T2
disease, 3 patients with T3 disease, and 3 patients with T4 disease).

Table A. Demographic characteristics
No. Pts. (%)
Study cohort
247 (100)
Mean age ± SD
70.5 ± 9.8
Males
244 (98.8)
Females
3 (1.2)
Clinical stage:
CIS
6 (2.4)
Ta
120 (48.6)
T1
81 (32.8)
T2
34 (13.8)
T3
3 (1.2)
T4
3 (1.2)
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The mean time interval from referral to the GU service to the diagnosis of
bladder cancer by TURBT (specialty delay) for the entire cohort was 179 days
(6.0 months). The specialty delay for the entire cohort ranged from 0 to 1,417
days, with a median of 100 days. Table B summarizes the specialty delay for all
patients stratified by clinical stage. A one-way ANOVA demonstrated that there
was no statistical difference of the mean specialty delays between the clinical
stages (p=0.96).

Table B. Specialty delays stratified by clinical stage. SEM=standard error
of measurement.
Clinical
No.
Mean Specialty
Range
SEM (days)
Stage
Pts.
Delay (days)
(days)
Ta
120
184
2-1288
20.2
T1
81
166
0-1417
27.4
T2
34
194
2-1086
48.1
T3
3
180
41-280
71.7
T4
3
233
24-647
207.0
CIS
6
151
29-465
66.8
The mean specialty delay for those patients with superficial disease,
defined as stage Ta and T1, was 176 days with a standard error of measurement
(SEM) of 12.0. The mean specialty delay for those patients with muscle-invasive
disease, defined as stage T2, T3, or T4, was 228 days (SEM 28.4). Figure 1
demonstrates that the patients presenting with muscle-invasive bladder cancer
have no statistically significant difference in specialty delay, in comparison to
those patients with superficial disease (Student’s t-test, two-tail p=0.10).
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Figure 1. Mean specialty delays for superficial disease (n=202) and muscleinvasive disease (n=41) [Student’s t-test, p=0.10].
Table C summarizes the incidence of bladder cancer recurrence on followup TURBT for those patients who were initially diagnosed with clinical stage Ta,
T1, or CIS bladder cancer. Bladder cancer recurrence was not chosen as an
endpoint for patients with muscle-invasive disease (T2-T4) since treatment with
radical cystectomy is the standard of care. The incidence of bladder cancer
recurrence was similar for patients with stage Ta, T1, and CIS disease. Table C
also summarizes the incidence of all cause death for the cohort stratified by
clinical stage. The patients with muscle-invasive bladder cancer (T2-T4) have a
two-fold increase in all-cause death, compared to the patients who present with
superficial bladder cancer (50.0% versus 25.4%, respectively, p=0.004). Patients
with stage Ta disease had the lowest incidence of all-cause death at 24.2% and
patients with stage T4 disease had the highest incidence of all cause death. On
regression analysis, there was a statistically significant correlation between
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increasing clinical stage and an increased incidence of all cause death (p=0.01,
see Figure 2).

Table C. Bladder cancer recurrence and death by any cause stratified by clinical
stage.
Clinical Stage
No. of Pts with
No. of Pts
Recurrence (%)
with AllCause Death
(%)
Ta (n=120)
55 (45.8)
29 (24.2)
T1 (n=81)
35 (43.2)
22 (27.2)
T2 (n=34)
-15 (44.1)
T3 (n=3)
-2 (66.7)
T4 (n=3)
-3 (100)
Superficial
90 (44.8)
51 (25.4)
(n=201)
Muscle-Invasive
-20 (50.0)
(n=40)

100.0

80.0

60.0
%
40.0

20.0

0.0
Ta

T1

T2

T3

T4

Clinical Stage

Figure 2. Incidence of death by any cause, demonstrating
an increased incidence of death with increased clinical stage
(regression analysis, p=0.01).
Figure 3 demonstrates a reduced incidence of bladder cancer recurrence
in those patients with a specialty delay of greater than 100 days compared to
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those patients with a diagnosis made 100 days or less, however the reduction
was not statistically significant for all groups. For those patients with superficial
disease (Ta and T1; n=201) and a specialty delay of greater than 100 days, there
was a trend towards a reduction in bladder cancer recurrence compared to those
patients with a specialty delay of 100 days or less (Relative Risk=0.78; 95% CI
0.57-1.06; p=0.12). Table D summarizes the relative risk of bladder cancer
recurrence for patients with a specialty delay of 100 days or less compared to
those with a specialty delay of greater than 100 days.

60
53.7
50.5

50

46.7

44.8

40

39.4

39.2

38.9

36.1

% 30

20

10

0
Cohort

Superficial

Ta

T1

Figure 3. Bladder tumor recurrence in patients with a specialty delay of 100
days or less (open boxes) compared to greater than 100 days (hatched boxes),
stratified by clinical stage.
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Table D. Relative risk of bladder cancer recurrence for specialist
delay >100 days compared to ≤100 days.
Specialist delay
Relative
95% CI
p-Value
>100 days
Risk
Entire Cohort
0.81
0.59-1.09
0.19
Superficial Disease
0.78
0.57-1.06
0.12
(Ta and T1)
Clinical Stage Ta
0.73
0.50-1.08
0.14
Clinical Stage T1
0.83
0.57-1.49
0.51
Figure 4 demonstrates a reduced incidence of all-cause death in those
patients with a specialty delay of greater than 100 days when compared to those
patients with a specialty delay of 100 days or less. For the entire cohort, patients
with a specialty delay of greater than 100 days had a decreased risk of death
compared to those with a specialty delay of 100 days or less (RR=0.59, 95% CI
0.36-0.90; p=0.01). For patients diagnosed with muscle-invasive bladder cancer,
there was no statistical difference in the incidence of all-cause death between
those patients diagnosed 100 days or less and those with a specialty delay of
greater than 100 days (see Table E). However, for patients diagnosed with
superficial bladder cancer, there was a statistically significant reduction in the
incidence of all-cause death for those patients with a specialty delay of greater
than 100 days compared to those with a shorter specialty delay (RR=0.53, 95%
CI 0.32-0.88; p=0.01). Patients with stage Ta disease also had a statistically
significant reduction in the incidence of all cause death (RR=0.50, 95% CI 0.260.97; p=0.05).
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Figure 4. All-cause mortality rate in patients with a specialty delay of 100 days
or less (open boxes) compared to greater than 100 days (hatched boxes).
*not statistically significant (p>0.05)

Table E. Relative risk of death from all causes for specialist
delay >100 days compared to ≤100 days.
Specialist delay
Relative
95% CI
p-Value
>100 days
Risk
Entire Cohort
0.59
0.36-0.90
0.01
Superficial Disease
0.53
0.32-0.88
0.01
(Ta and T1)
Muscle-Invasive
0.81
0.41-1.57
0.75
Disease (T2-T4)
Clinical Stage Ta
0.50
0.26-0.97
0.05
Clinical Stage T1
0.58
0.27-1.28
0.21
Clinical Stage T2
0.71
0.31-1.64
0.50
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DISCUSSION
It is difficult to compare the median specialty delay of 100 days found in
this study to delays found in other studies because of the various different
definitions of diagnostic delays. Wallace et al. (23) have the most similar
definition, with a specialist delay defined as the date of general practitioner (GP)
referral to the date of first treatment by transurethral resection of bladder tumor
(TURBT). They reported a median specialist delay of 68 days (range 34-118
days), which is over one month shorter than the median delay observed in this
study at the VA Connecticut Healthcare System. Liedberg et al. (18) defined a
diagnostic delay as the time lag from the patient’s first awareness of symptoms to
the establishment of a correct diagnosis, and observed a median diagnostic
delay of 144 days. This diagnostic delay definition includes the patient delay,
defined as the time lag from the patient’s first awareness of symptoms to the first
medical consultation, and the hospital delay, defined as the time lag from that
consultation to the establishment of a diagnosis. Unfortunately, a direct
comparison to this study cannot be made since they did not report the specialist
delay separately from the diagnostic delay. Mansson et al. (22) studied the
hospital delay in 343 patients diagnosed with bladder cancer and observed a
median hospital delay of 62 days. The hospital delay of 62 days observed by
Mansson et al. (22) is considerably shorter than the median specialty delay of
100 days observed in this study, especially given the fact that the hospital delay
includes the delay from first medical consultation to specialist consultation.
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When the specialty delay was stratified by clinical stages, there was no
difference observed in the mean delays. This observation could be the result of
low sample sizes in each clinical stage, especially for stage T3 and T4, which
had three patients in each group. The low sample size in these two groups led to
high standard errors of the mean, which contributes to the statistical analysis.
However, when the clinical stages were grouped into superficial disease (stage
Ta and T1) and muscle-invasive disease (stage T2-T4), there was a more
pronounced difference in the mean specialty delays. The muscle-invasive group
had a mean specialty delay that was 52 days longer than the superficial group
(228 days versus 176 days; p=0.10). Although the difference was not statistically
significant, a trend was seen towards a longer specialty delay with more
advanced clinical stage. This result is consistent with observations made in the
Swedish study by Liedberg et al. (18). They observed a median diagnostic delay
of 124 days and 157 days in the T1 and T2-T4 tumor groups, respectively. When
they compared the diagnostic delays for each tumor stage, there was a
significantly longer diagnostic delay in patients presenting with more advanced
tumor stages (test for trend, p=0.02).
Our study observed a statistically significant increased incidence of allcause mortality with more advanced tumor stage (p=0.01). Recent studies have
found a similar relationship between advanced tumor stage and mortality.
Wallace et al. (23) observed a significant association between death and tumor
stage, indicating that patients with T2-T4 tumors were more likely to die from
bladder cancer than patients with Ta and T1 tumors (test for trend, p<0.001).
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Similarly, Liedberg et al. (18) found that tumor stage strongly correlated (p<0.001)
with cumulative incidence of bladder cancer death.
The hypothesis for our study was that a prolonged specialty delay in
patients newly diagnosed with bladder cancer would result in a worse prognosis
compared to those patients with a shorter delay. However, the results of this
study did not confirm this hypothesis. In fact, there was a paradoxical finding that
patients with a specialty delay greater than the median delay of 100 days had a
better prognosis. Patients who were newly diagnosed with bladder cancer within
100 days from the consultation to the GU service had a higher all-cause mortality
rate than those patients diagnosed after 100 days (36% versus 21.3%,
respectively). The reduction in the all-cause mortality rate was statistically
significant in those patients with a specialty delay greater than 100 days,
compared to those with a delay of 100 days or less (RR=0.59; 95% CI 0.36-0.90;
p=0.01). In a U.K. study by Wallace et al. (23) a similar relationship was
observed between hospital delay and survival. They studied 1,537 patients and
compared overall survival between those patients with a hospital delay of 68
days or less and those patients with a hospital delay of greater than 68 days.
They observed that the patients with a shorter hospital delay (68 days or less)
had a significantly worse overall survival in comparison to the patients with a
prolonged hospital delay (p=0.001). Even after adjusting for tumor stage, the
worse overall survival seen in the shorter hospital delay group continued to be
statistically significant (p=0.01).
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When the patients with superficial disease (stage Ta and T1) in our study
were analyzed separately, a statistically significant reduction in all-cause
mortality continued to be observed in the group with a specialty delay of more
than 100 days (RR=0.53; 95% CI 0.32-0.88; p=0.01). Although the patients with
muscle-invasive disease (stage T2-T4) who had a specialty delay of more than
100 days had a lower all-cause mortality rate compared to those diagnosed
within 100 days, it was not statistically significant (p=0.75). These findings are
not consistent with those observed in a Swedish study by Liedberg et al. (18)
who studied the affects of diagnostic delays on bladder cancer death in 177
patients with bladder cancer. They found that among patients with T1 tumors,
those with a diagnostic delay of more than 6 months showed a trend, although
not statistically significant, towards an increased risk of bladder cancer death
(RR=2.0; 95% CI 0.84-4.7; p=0.12). They also observed that in the group with
muscle-invasive tumors (T2-T4) who had a diagnostic delay of more than 6
months, had a statistically significant reduction in bladder cancer death (RR=0.39;
95% CI 0.23-0.69; p=0.001). A possible contributing factor to the significant
result Liedberg et al. (18) were able to observe in the muscle-invasive group,
compared to the observation seen in our study could be due to the difference in
sample size. The Swedish study had 103 patients in the muscle-invasive group,
compared to 40 patients in our study.
The findings of our study initially seem counter-intuitive, but biased patient
selection could explain why an increased specialty delay is associated with
improved prognosis. Those patients who were found to have large, solid-looking
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tumors at flexible cystocopy in the office may have been prioritized for early
transurethral resection and conversely, patients found to have small, papillary
tumors at flexible cystoscopy may have been considered as requiring
transurethral resection less urgently. This triage effect is predominantly seen in
hospital settings with limited resources, resulting in longer wait times for
operating room scheduling and physician availability to perform transurethral
resection of the bladder tumor (TURBT). Thus, patients with rapidly progressing
tumors with a poor prognosis might have undergone early TURBT and diagnosis
after visualization of the tumor by flexible cystoscopy and triaging by the
specialist in the outpatient setting. To study diagnostic delay without the triage
effect would require a hospital setting with an excess of resources available to
eliminate the scheduling delays for TURBT. In this scenario, every patient would
have access to timely TURBT regardless of the appearance of the patient’s
bladder tumor on flexible cystoscopy.
The patient’s presenting symptoms, such as gross hematuria versus
microhematuria, may have also altered decisions about the priority of
transurethral resection. Mansson et al. (22) studied delays in diagnosis, and
found that the hospital delay (time interval from first medical consultation to the
establishment of a correct diagnosis) was strongly influenced by the presenting
symptoms of the patient. The median hospital delay for patients presenting with
hematuria plus pain was 44 days, for hematuria alone was 53 days, and for
urgency of micturition alone was 114 days (p<0.001). The severity of signs and
symptoms at presentation may perhaps influence the speed of the medical

27
decision process and give patients with severe disease priority for diagnosis and
treatment, which could correlate with worse prognosis.
Studies of diagnostic delays in other malignancies have also
demonstrated an improved survival in patients with longer delays (20, 21, 24).
Rupassara et al. (20) studied 154 patients diagnosed with colorectal cancer and
divided the study group into a Late group and an Early group. The Late group
was defined as patients who had to wait more than or equal to 50 days from the
date of receipt of a referral letter to the date of diagnosis. The Early group was
comprised of patients who had a referral to diagnosis time less than 50 days.
They found that the Late group had a 93.7% cancer-specific five year survival,
compared with 65.3% in the Early group (p=0.007). Similar findings have been
observed in studies of patients diagnosed with lung cancer. Salomaa et al. (21)
studied 132 patients diagnosed with lung cancer and measured different delays
from first symptoms to treatment. They looked at the specialist treatment delay
(delay time between the first visit to the specialist and the date of the beginning
of treatment) in relation to survival. They found that patients with a delay longer
than the median time had a 40% lower risk of dying compared with the patients
with a shorter delay (hazard ratio=0.60; 95% CI 0.39-0.91; p=0.02). Even when
studying a specific type of lung cancer, Myrdal et al. (24) observed a survival
advantage for those patients with longer delays who were diagnosed with nonsmall cell lung cancer. They studied 466 patients diagnosed with non-small cell
lung cancer and measured two types of delay, symptom to treatment delay and
hospital delay. They found that patients with symptom to treatment delays of
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less than 3 months had a 3-year survival of 11%, while patients with a delay of
more than 6 months had a survival of 35%. They also found similar results when
analyzing the relationship between hospital delay and survival. Patients with the
shortest hospital delay (less than one month) had a 3-year survival of 19%
compared to 43% for those patients with a hospital delay of more than 3 months.
These results indicate that longer delay times are not associated with a poor
prognosis. On the contrary, the prognosis was poorer in patients with a shorter
delay.
The findings of our study revealed an inverse relationship between
increased specialty delay and risk of all-cause mortality; however, the authors
recognize the limitations of this study. As mentioned above, there was an
inadequate sample size for the muscle-invasive disease groups, especially for
stage T3 and T4, which had three patients each. In addition, some of the
patients with muscle-invasive disease never received curative treatment with
radical cystectomy due to comorbidities or the patient’s refusal of treatment. Of
the 40 patients who had muscle-invasive disease (stage T2-T4), only 17 patients
(42.5%) were treated with radical cystectomy (data not shown). This finding is
consistent with a Swedish study by Holmang et al. (25), who found that only 40%
of patients with muscle-invasive bladder cancer were considered fit for radical
cystectomy. Since this was a retrospective study reviewing the medical records
of the study subjects, there was inadequate data collection on the cause of death
and date of first symptoms. Thus, only overall mortality was calculated and
disease-specific mortality was omitted from the analysis. In addition, complete
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data on the dates of symptom onset would have made calculation of patient’s
delay (time interval from onset of symptoms to first medical consultation) possible.
Without the data on patient’s delay, an accurate description of the diagnostic
delay (time interval from onset of symptoms to the establishment of a diagnosis)
cannot be made. Instead, this study only used the specialty delay in the analysis,
without taking into account the amount of time the patients have been
symptomatic, which could contribute to the patient’s outcome. Another limitation
of this study is the omission of a multivariate analysis, which could have
investigated factors such as age and comorbidity conditions that can affect
survival from cancer. It is possible that the patients with shorter specialty delays
had more comorbidities that may have subsequently determined the outcome,
and not bladder cancer.
In general, there is a natural assumption that the sooner physicians can
diagnose a cancer, the greater will be the chance of discovering it before it
progresses and becomes incurable. However, this study did not confirm this
assumption. In this study, there was a paradoxical finding that patients
diagnosed more than 100 days after referral had a significant improvement in
prognosis. In a society that is becoming increasingly litigious, one cannot rule
out the possibility of a litigation based on a delayed diagnosis of cancer.
Although this study observed a median specialty delay that is considerably longer
than observed in other studies, the data demonstrates, within reasonable limits,
that a patient in this healthcare system can be reassured that a delayed
diagnosis is appears not to alter their prognosis. Even though our results
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indicate that a longer delay before diagnosis of bladder cancer is not associated
with a poorer prognosis, a timely diagnosis is still in the best interest of the
patient’s mental well-being. Requiring patients to wait longer for their diagnosis
can cause additional psychological stress. Providing an early diagnosis can
eliminate the guilt felt by patients for prolonging the patient delay interval and
eliminate the blaming of the healthcare services for a long hospital delay.
In conclusion, our study observed a significant reduction in all-cause
mortality for those patients diagnosed more than 100 days from consultation to
the genitourinary service. In this setting, the triage effect may play an important
role in the results observed in this study. However, to study this relationship
without the triage effect would require a healthcare system with an excess of
hospital resources or determination by a prospective study, which would be
unethical to knowingly delay a patient’s diagnosis of bladder cancer. These
paradoxical findings confirm that the relationship between diagnostic delay and
mortality is complex, and requires further investigation.
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